Dr. Clay Siegall is the co-founder and the current President of Seattle Genetics. He enjoys many of experience in cancer-related medical services. He has a great passion for giving better treatment options to cancer patients by focusing on drugs that will and are supporting the patients. As the company’s CEO and chairman of Directors Board, he has been able to focus on developing various antibody-based cancer therapies.
Seattle Genetics was established in 1997. Today, Clay Siegall has transformed the company to a medical powerhouse in cancer research space. He sets enormous targets and plans for the company whereby the company has increased its drug varieties in recent years. Seattle Genetics has been able to create and sell their drugs through a professional sales team that has medical treatment understanding. The Company also generates revenues by licensing their invented methods and procedures to other companies.
He envisions that the world needs better solutions other than the common cancer therapies that have been done on patients. He points out that his passion for specializing in cancer research and treatment came when he lost a close family member to cancer. He strongly believes that the relative succumbed due to harsh chemotherapy, he was subjected to. Dr. Siegall has the vision to create better ways to treat cancer patients. He targets to improve cancer therapies come up with more effective drugs.
Dr. Siegall holds a degree in Bachelor of Science in zoology from the University of Maryland, and a Ph.D. in Genetics awarded at George Washington University. Apart from establishing Seattle Genetics, he has worked with various organizations in his career life. In 1991, he worked as a senior researcher at Bristol-Myers Pharmaceutical where he was later appointed as a Principal Scientist until the end of 1997. He became the CEO of Seattle Genetics in 2000 before taking over as its President. He also serves as one of the directors of Alder Biopharmaceuticals and also serves on the Board of Governors at the Fred Hutchinson Cancer Research Business Alliance.
Siegall’s efforts to control cancer have seen him receive various recognitions. Due to his undertakings in the area of targeted toxins was recognized and presented with the Pierce Award in 1995. In 2002, he was named the Ernst and Young Pacific Northwest Entrepreneur of the Year grant finalist in the medical category.